Nirmatrelvir and ritonavir combination against COVID‐19 caused by omicron BA.2.2 in the elderly: A single‐center large observational study
Can Chen, Ranyi Li, Shuliang Xing, Lei Cao, Yue Qu, Qianzhou Lv, Xiaoyu Li, Zhangzhang Chen
Immunity, Inflammation and Disease, doi:10.1002/iid3.1232
Background: Since coronavirus 2019 (COVID-19) swept the world, a variety of novel therapeutic and prevention strategies have been developed, among which nirmatrelvir-ritonavir is highly recommended. We intended to assess the effectiveness and safety of nirmatrelvir-ritonavir in the elderly mild-tomoderate COVID-19 population caused by the omicron BA.2.2 variant in realworld settings. Methods: An observational study was conducted retrospectively to review the outcomes of mild-to-moderate COVID-19 patients admitted between April 26 and June 30, 2022. Patients' baseline characteristics were collected and assessed. Participants in the intervention group were administered nirmatrelvir-ritonavir in addition to standard care, whereas those in the control group only received standard care. The primary outcome was the duration between the initial positive reverse-transcription polymerase chain reaction (RT-PCR) test and the subsequent conversion to a negative result. Results: The analysis included 324 patients who were administered nirmatrelvir-ritonavir and an equal number of control patients. The patient characteristics in both groups were evenly matched. The average duration from the initial positive RT-PCR to negative conversion was similar in both groups (16.2 ± 5.0 vs. 16.1 ± 6.3 days, p = .83). Control patients exhibited slower conversion in comparison to patients who received nirmatrelvir-ritonavir treatment within 10 days of symptom onset. Conclusions: These findings suggest that administering nirmatrelvirritonavir within 10 days of symptom onset could potentially reduce the time
AUTHOR CONTRIBUTIONS Can Chen: Investigation; methodology; writingoriginal draft; writing-review and editing. Ranyi Li: Data curation; formal analysis; software; writing-review and editing. Shuliang Xing: Project administration; resources; supervision. Lei Cao: Project administration; resources; supervision. Yue Qu: Methodology; writingreview and editing. Qianzhou Lv: Supervision. Xiaoyu Li: Conceptualization; data curation; funding acquisition; writing-review and editing. Zhangzhang Chen: Conceptualization; data curation; formal analysis; writing-review and editing.
CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest.
ETHICS STATEMENT This study adhered to STROBE guidelines and received approval from the ethics committees of Zhongshan Hospital, Fudan University (approval number B2022-470R).
References
Dal-Ré, Becker, Bottieau, Holm, Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach, Lancet Infect Dis
Docherty, Harrison, Green, Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study, BMJ
Drew, Donnell, Leblanc, Mcmahon, Natin, The importance of cycle threshold values in interpreting molecular tests for SARS-CoV-2, Diagn Microbiol Infect Dis
Dryden-Peterson, Kim, Kim, Nirmatrelvir plus ritonavir for early covid-19 in a large U.S. health system: a population-based cohort study, Ann Intern Med
Hammond, Leister-Tebbe, Gardner, Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19, N Engl J Med
Kaboré, Laffont, Diop, Real-world effectiveness of nirmatrelvir/ritonavir on coronavirus disease 2019-associated hospitalization prevention: a population-based cohort study in the province of Quebec, Canada, Clin Infect Dis
Kim, Garg, 'halloran, Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network (COVID-NET), Clin Infect Dis
Krammer, SARS-CoV-2 vaccines in development, Nature
Lewnard, Mclaughlin, Malden, Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system, Lancet Infect Dis
Li, Gao, You, Association of nirmatrelvir/ ritonavir treatment on upper respiratory severe acute respiratory syndrome coronavirus 2 reverse transcription-polymerase chain reaction (SARS-CoV-2 RT-PCR) negative conversion rates among high-risk patients with coronavirus disease 2019 (COVID-19), Clin Infect Dis
Martin-Blondel, Marcelin, Soulié, Time to negative PCR conversion amongst high-risk patients with mild-to-moderate omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir, Clin Microbiol Infect
Owen, Allerton, Anderson, An oral SARS-CoV-2 mpro inhibitor clinical candidate for the treatment of COVID-19, Science
Pan, Peto, Henao-Restrepo, Repurposed antiviral drugs for Covid-19-interim WHO solidarity trial results, N Engl J Med
Pitre, Van Alstine, Chick, Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis, Can Med Assoc J
Rao, Manissero, Steele, Pareja, A systematic review of the clinical utility of cycle threshold values in the context of COVID-19, Infect Dis Ther
Rodríguez-Grande, Jiménez, Catalán, Inference of active viral replication in cases with sustained positive reverse transcription-PCR results for SARS-CoV-2, J Clin Microbiol
Salvatore, Dawson, Wadhwa, Epidemiological correlates of polymerase chain reaction cycle threshold values in the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis
Sevrioukova, Poulos, Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir, Proc Natl Acad Sci
Singh, Toussi, Hackman, Innovative randomized phase I study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of nirmatrelvir, Clin Pharm Ther
Stein, Ramelli, Grazioli, SARS-CoV-2 infection and persistence in the human body and brain at autopsy, Nature
Ullrich, Ekanayake, Otting, Nitsche, Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir, Bioorg Med Chem Lett
Vangeel, Chiu, Jonghe, Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 omicron and other variants of concern, Antiviral Res
Wong, Au, Lau, Lau, Cowling et al., Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study, Lancet
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention, JAMA
Zhang, Liang, Tang, Negative conversion rate of SARS-CoV-2 infection, JAMA Int Med
Zhang, Zhang, Chen, Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic, Lancet
{ 'indexed': {'date-parts': [[2024, 4, 6]], 'date-time': '2024-04-06T00:55:43Z', 'timestamp': 1712364943687},
'reference-count': 29,
'publisher': 'Wiley',
'issue': '4',
'license': [ { 'start': { 'date-parts': [[2024, 4, 5]],
'date-time': '2024-04-05T00:00:00Z',
'timestamp': 1712275200000},
'content-version': 'vor',
'delay-in-days': 4,
'URL': 'http://creativecommons.org/licenses/by/4.0/'}],
'content-domain': {'domain': ['onlinelibrary.wiley.com'], 'crossmark-restriction': True},
'published-print': {'date-parts': [[2024, 4]]},
'abstract': '<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Since '
'coronavirus 2019 (COVID‐19) swept the world, a variety of novel therapeutic and prevention '
'strategies have been developed, among which nirmatrelvir–ritonavir is highly recommended. We '
'intended to assess the effectiveness and safety of nirmatrelvir–ritonavir in the elderly '
'mild‐to‐moderate COVID‐19 population caused by the omicron BA.2.2 variant in real‐world '
'settings.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>An '
'observational study was conducted retrospectively to review the outcomes of mild‐to‐moderate '
"COVID‐19 patients admitted between April 26 and June 30, 2022. Patients' baseline "
'characteristics were collected and assessed. Participants in the intervention group were '
'administered nirmatrelvir–ritonavir in addition to standard care, whereas those in the '
'control group only received standard care. The primary outcome was the duration between the '
'initial positive reverse‐transcription polymerase chain reaction\xa0(RT‐PCR)\xa0test and the '
'subsequent conversion to a negative '
'result.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The analysis '
'included 324 patients who were administered nirmatrelvir–ritonavir and an equal number of '
'control patients. The patient characteristics in both groups were evenly matched. The average '
'duration from the initial positive RT‐PCR to negative conversion was similar in both groups '
'(16.2\u2009±\u20095.0 vs. 16.1\u2009±\u20096.3 days, <jats:italic>p</jats:italic>\u2009=\u2009'
'.83). Control patients exhibited slower conversion in comparison to patients who received '
'nirmatrelvir–ritonavir treatment within 10 days of symptom '
'onset.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>These '
'findings suggest that administering nirmatrelvir–ritonavir within 10 days of symptom onset '
'could potentially reduce the time it takes for SARS‐CoV‐2‐infected patients to negative '
'RT‐PCR results, thereby expanding the current usage guidelines for '
'nirmatrelvir–ritonavir.</jats:p></jats:sec>',
'DOI': '10.1002/iid3.1232',
'type': 'journal-article',
'created': {'date-parts': [[2024, 4, 5]], 'date-time': '2024-04-05T12:14:31Z', 'timestamp': 1712319271000},
'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Nirmatrelvir and ritonavir combination against COVID‐19 caused by omicron BA.2.2 in the elderly: '
'A single‐center large observational study',
'prefix': '10.1002',
'volume': '12',
'author': [ { 'given': 'Can',
'family': 'Chen',
'sequence': 'first',
'affiliation': [ { 'name': 'Department of Pharmacy, Zhongshan Hospital Fudan University '
'Shanghai China'}]},
{ 'given': 'Ranyi',
'family': 'Li',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Pharmacy, Zhongshan Hospital Fudan University '
'Shanghai China'}]},
{ 'given': 'Shuliang',
'family': 'Xing',
'sequence': 'additional',
'affiliation': [ { 'name': 'Science and Education Office Shanghai Geriatric Medical Center '
'Shanghai China'}]},
{ 'given': 'Lei',
'family': 'Cao',
'sequence': 'additional',
'affiliation': [ { 'name': 'Medical Administration Office, Zhongshan Hospital Fudan '
'University Shanghai China'}]},
{ 'given': 'Yue',
'family': 'Qu',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Infectious Diseases The Alfred Hospital and Monash '
'University Clayton Australia'}]},
{ 'given': 'Qianzhou',
'family': 'Lv',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Pharmacy, Zhongshan Hospital Fudan University '
'Shanghai China'}]},
{ 'given': 'Xiaoyu',
'family': 'Li',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Pharmacy, Zhongshan Hospital Fudan University '
'Shanghai China'}]},
{ 'ORCID': 'http://orcid.org/0009-0009-9468-7782',
'authenticated-orcid': False,
'given': 'Zhangzhang',
'family': 'Chen',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Pharmacy, Zhongshan Hospital Fudan University '
'Shanghai China'}]}],
'member': '311',
'published-online': {'date-parts': [[2024, 4, 5]]},
'reference': [ {'key': 'e_1_2_12_2_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2023184'},
{'key': 'e_1_2_12_3_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41586-020-2798-3'},
{ 'key': 'e_1_2_12_4_1',
'unstructured': 'Therapeutics and COVID‐19. Accessed January 26 '
'2024.https://reliefweb.int/attachments/d44a29d7-fdee-4045-ac26-fc632f98fcde/WHO-2019-nCoV-therapeutics-2023.2-eng.pdf'},
{'key': 'e_1_2_12_5_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1503/cmaj.220471'},
{'key': 'e_1_2_12_6_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1126/science.abl4784'},
{ 'key': 'e_1_2_12_7_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.antiviral.2022.105252'},
{'key': 'e_1_2_12_8_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.bmcl.2022.128629'},
{'key': 'e_1_2_12_9_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/cpt.2603'},
{ 'key': 'e_1_2_12_10_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/S1473-3099(22)00119-0'},
{'key': 'e_1_2_12_11_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1073/pnas.1010693107'},
{'key': 'e_1_2_12_12_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2118542'},
{ 'key': 'e_1_2_12_13_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/S1473-3099(23)00118-4'},
{'key': 'e_1_2_12_14_1', 'doi-asserted-by': 'publisher', 'DOI': '10.7326/M22-2141'},
{ 'issue': '4',
'key': 'e_1_2_12_15_1',
'doi-asserted-by': 'crossref',
'first-page': '543.e5',
'DOI': '10.1016/j.cmi.2022.12.016',
'article-title': 'Time to negative PCR conversion amongst high‐risk patients with '
'mild‐to‐moderate omicron BA.1 and BA.2 COVID‐19 treated with sotrovimab '
'or nirmatrelvir',
'volume': '29',
'author': 'Martin‐Blondel G',
'year': '2023',
'journal-title': 'Clin Microbiol Infect'},
{'key': 'e_1_2_12_16_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciac600'},
{'key': 'e_1_2_12_17_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciad287'},
{ 'key': 'e_1_2_12_18_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/S0140-6736(22)01586-0'},
{ 'key': 'e_1_2_12_19_1',
'unstructured': 'National Medical Products Administration of China. Emergency conditional '
"approval of Pfizer's COVID‐19 therapy:nirmatrelvir tablet/ritonavir "
'tablet combination package (i.e. Paxlovid) importation registration [in '
'Chinese]. Accessed April 27 \xa0'
'2022.https://www.nmpa.gov.cn/yaowen/ypjgyw/20220212085753142'},
{ 'key': 'e_1_2_12_20_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/S0140-6736(22)00838-8'},
{ 'key': 'e_1_2_12_21_1',
'unstructured': "National Health Commission of the People's Republic of China. Diagnosis "
'and treatment protocol for COVID‐19 (trial version 9) [in Chinese]. '
'Accessed June 20 '
'2022.http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=b74ade1ba4494583805a3d2e40093d88'},
{'key': 'e_1_2_12_22_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.m1985'},
{'key': 'e_1_2_12_23_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciaa1012'},
{'key': 'e_1_2_12_24_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2020.2648'},
{ 'key': 'e_1_2_12_25_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.diagmicrobio.2020.115130'},
{ 'issue': '4',
'key': 'e_1_2_12_26_1',
'doi-asserted-by': 'crossref',
'first-page': '566',
'DOI': '10.1001/jamainternmed.2020.7201',
'article-title': 'Negative conversion rate of SARS‐CoV‐2 infection',
'volume': '181',
'author': 'Zhang R',
'year': '2021',
'journal-title': 'JAMA Int Med'},
{'key': 'e_1_2_12_27_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciaa1469'},
{ 'key': 'e_1_2_12_28_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1007/s40121-020-00324-3'},
{ 'key': 'e_1_2_12_29_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/s41586-022-05542-y'},
{ 'issue': '2',
'key': 'e_1_2_12_30_1',
'doi-asserted-by': 'crossref',
'DOI': '10.1128/JCM.02277-20',
'article-title': 'Inference of active viral replication in cases with sustained positive '
'reverse transcription‐PCR results for SARS‐CoV‐2',
'volume': '59',
'author': 'Rodríguez‐Grande C',
'year': '2021',
'journal-title': 'J Clin Microbiol'}],
'container-title': 'Immunity, Inflammation and Disease',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1002/iid3.1232',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2024, 4, 5]],
'date-time': '2024-04-05T12:14:35Z',
'timestamp': 1712319275000},
'score': 1,
'resource': {'primary': {'URL': 'https://onlinelibrary.wiley.com/doi/10.1002/iid3.1232'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2024, 4]]},
'references-count': 29,
'journal-issue': {'issue': '4', 'published-print': {'date-parts': [[2024, 4]]}},
'alternative-id': ['10.1002/iid3.1232'],
'URL': 'http://dx.doi.org/10.1002/iid3.1232',
'relation': {},
'ISSN': ['2050-4527', '2050-4527'],
'subject': ['Immunology', 'Immunology and Allergy'],
'container-title-short': 'Immunity Inflam &amp; Disease',
'published': {'date-parts': [[2024, 4]]},
'assertion': [ { 'value': '2023-11-13',
'order': 0,
'name': 'received',
'label': 'Received',
'group': {'name': 'publication_history', 'label': 'Publication History'}},
{ 'value': '2024-03-14',
'order': 1,
'name': 'accepted',
'label': 'Accepted',
'group': {'name': 'publication_history', 'label': 'Publication History'}},
{ 'value': '2024-04-05',
'order': 2,
'name': 'published',
'label': 'Published',
'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
